Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Tumor Boards
Colleague Insights
Living Resources
Conferences
Nursing Perspectives
Video Expert Opinion
Sign in
Join now
featured
Published in Metastatic Breast Cancer

Expert Opinion / Cases · March 05, 2018

Locally Advanced Breast Cancer With Partial Response to Neo-Adjuvant Chemotherapy

Sameer Nasir MD

 

 Save  Recommend
 Share

Discuss This item Follow

No comments yet, be the first to start the discussion!

  • Ganta Ranga raman

    Mar 05, 2018

    RT + endocrine therapy. No adjuvant chemotherapy

  • Krzysztof Lesniewski-Kmak

    Mar 05, 2018

    Capecitabine can be used, but I wouldn't; benefit from it was seen rather between triple negative cancer patients.
  • Comment deleted by Moderator.

  • Damnern Vachirodom

    Mar 08, 2018

    AIs+RT

  • fatma seghier

    Mar 09, 2018

    No adjuvant chemotherapy, only AA with radiotherapy

  • Adriana Lobos

    Mar 09, 2018

    Hormonoterapia y radiorerapia

  • Agnieszka Jagiello-Gruszfeld

    Mar 09, 2018

    AI and radiotherapy, no chemo

  • Levon Badalyan

    Mar 09, 2018

    Residual cancer cells of initially LuminalB breast tumor are usually Chemoresistant, because Chemosensitive ones getting killed by such a long and intensive chemotherapy. It is kind of a conversion from LuminalB to LuminalA subtypes. In such cases i prefer to recheck the ER/PR expression on postchemotherapy tissue, if it still positive, it is better not to lose time with Capecitabine and start Endocrine treatment. In case of conversion to Triple Negative subtype, we have to consider Capecitabine.

  • Mark Moskowitz

    Mar 09, 2018

    Would not give capecitabine in ER+ patient; agree with AI + RT

  • Ayyappan Palanisamy

    Mar 10, 2018

    Sir,
RT +two years Tamoxifen then 3years AI.
During AI ,to add 6 month once zoledronic acid
Daily calcium  and vitD.

  • Fatma Sen

    Mar 11, 2018

    She is candidate for adjuvant aromatase inhibitor and Rt. I recommend adj bisphosphonate

  • Aaron Santos

    Mar 15, 2018

    Aromatase inhibitor and RT only. There is insufficient evidence for capecitabine outside the triple negative scenario, I think

  • Moz Al ameri

    Mar 17, 2018

    I would go for adjuvante hormonal therapy and radiation 
Capcitabine is more effective in negative Hormone receptors

  • gema aguil

    Mar 23, 2018

    RT plus capecitabine and HT

  • MUFID ELMISTIRI

    Mar 26, 2018

    AI plus Radiotherapy, no place for further chemotherapy outside of clinic trials.

  • Jorge Perez

    Mar 27, 2018

    I would consider non cross-resistant adjuvant therapy. There was a nodal clone of surviving cancer cells resistant to induction chemotherapy agents that may progress to distant metastatic disease. We happily use blindly (without knowledge of sensitivity or response in a particular patient) adjuvant chemotherapy on any node positive disease, why would we not use adjuvant therapy on this patient in whom we do know it has nodal disease, resistant to prior therapy?

  • Dec 23, 2024

    Pending Moderator approval.
    Delete

Further Reading

Most Read This Week

Recently Updated